In vitro cytotoxicity studies of the plumbagin-loaded nanoemulsion showed a slightly augmented antiproliferative effect of the active pharmaceutical ingredient (plumbagin) against PTEN-P2 prostate cancer cells compared to free drug. The gene discussed is PTEN; the disease is prostate carcinoma.